Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply

Lancet. 2024 Aug 17;404(10453):657-658. doi: 10.1016/S0140-6736(24)00801-8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Bevacizumab / therapeutic use
  • Carcinoma, Hepatocellular* / drug therapy
  • Chemotherapy, Adjuvant
  • Humans
  • Immune Checkpoint Inhibitors
  • Liver Neoplasms* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents
  • atezolizumab
  • Immune Checkpoint Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab